Evidence map›Paper›PMID 40791867›Full record

ArticleMedComm2025

Blood Microbiome Reveals the Impact of

Ya-Shang Zheng, Wu-Hao Lin, Jun-Quan Chen, Xiao-Li Wei, Jia-Qian Huang, Yu-Hong Xu, Meng Yang, Qi-Hua Zhang, Zhi-Jun Zuo, Zhao-Ying Yang and 6 more

Abstract read
In one paragraph

Article in MedComm, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Ya-Shang ZhengDepartment of Medical Oncology State Key Laboratory of Oncology in South China Collaborative Innovation Center for Cancer Medicine Guangdong Provincial Clinical Research Center for Cancer Sun Yat-Sen University Cancer Center Guangzhou People's Republic of China.
Wu-Hao LinDepartment of Molecular Diagnostics State Key Laboratory of Oncology in South China Collaborative Innovation Center for Cancer Medicine Guangdong Provincial Clinical Research Center for Cancer Sun Yat-Sen University Cancer Center Guangzhou People's Republic of China.
Jun-Quan ChenDepartment of Anesthesiology Sun Yat-Sen University Cancer Center State Key Laboratory of Oncology in South China Collaborative Innovation Center for Cancer Medicine Guangzhou People's Republic of China.
Xiao-Li WeiDepartment of Medical Oncology State Key Laboratory of Oncology in South China Collaborative Innovation Center for Cancer Medicine Guangdong Provincial Clinical Research Center for Cancer Sun Yat-Sen University Cancer Center Guangzhou People's Republic of China.
Jia-Qian HuangDepartment of Medical Oncology State Key Laboratory of Oncology in South China Collaborative Innovation Center for Cancer Medicine Guangdong Provincial Clinical Research Center for Cancer Sun Yat-Sen University Cancer Center Guangzhou People's Republic of China.
Yu-Hong XuDepartment of Medical Oncology State Key Laboratory of Oncology in South China Collaborative Innovation Center for Cancer Medicine Guangdong Provincial Clinical Research Center for Cancer Sun Yat-Sen University Cancer Center Guangzhou People's Republic of China.
Meng YangDepartment of Medical Oncology State Key Laboratory of Oncology in South China Collaborative Innovation Center for Cancer Medicine Guangdong Provincial Clinical Research Center for Cancer Sun Yat-Sen University Cancer Center Guangzhou People's Republic of China.
Qi-Hua ZhangDepartment of Medical Oncology State Key Laboratory of Oncology in South China Collaborative Innovation Center for Cancer Medicine Guangdong Provincial Clinical Research Center for Cancer Sun Yat-Sen University Cancer Center Guangzhou People's Republic of China.
Zhi-Jun ZuoDepartment of Medical Oncology State Key Laboratory of Oncology in South China Collaborative Innovation Center for Cancer Medicine Guangdong Provincial Clinical Research Center for Cancer Sun Yat-Sen University Cancer Center Guangzhou People's Republic of China.
Zhao-Ying YangDepartment of Medical Oncology State Key Laboratory of Oncology in South China Collaborative Innovation Center for Cancer Medicine Guangdong Provincial Clinical Research Center for Cancer Sun Yat-Sen University Cancer Center Guangzhou People's Republic of China.
Pan ZhangSun Yat-Sen University Zhongshan School of Medicine Guangzhou People's Republic of China.
Nga Ki HongSun Yat-Sen University Zhongshan School of Medicine Guangzhou People's Republic of China.
Lu-Xuan LiuSun Yat-Sen University Zhongshan School of Medicine Guangzhou People's Republic of China.
Zhao-Lei ZengDepartment of Medical Oncology State Key Laboratory of Oncology in South China Collaborative Innovation Center for Cancer Medicine Guangdong Provincial Clinical Research Center for Cancer Sun Yat-Sen University Cancer Center Guangzhou People's Republic of China.
Rui-Hua XuDepartment of Medical Oncology State Key Laboratory of Oncology in South China Collaborative Innovation Center for Cancer Medicine Guangdong Provincial Clinical Research Center for Cancer Sun Yat-Sen University Cancer Center Guangzhou People's Republic of China.
Hui-Yan LuoDepartment of Medical Oncology State Key Laboratory of Oncology in South China Collaborative Innovation Center for Cancer Medicine Guangdong Provincial Clinical Research Center for Cancer Sun Yat-Sen University Cancer Center Guangzhou People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immunotherapy has revolutionized the treatment of gastrointestinal (GI) cancers, but reliable biomarkers for predicting treatment efficacy remain limited. In this study, we explored the potential of blood microbiome and specific microbial taxa as novel biomarkers for predicting the efficacy of immunotherapy combined with chemotherapy in GI cancer patients through 16S rRNA sequencing. Our findings demonstrated that lower baseline alpha diversity and specific microbial compositions, particularly lower levels of

Indexed as

biomarkerblood microbiomeefficacyimmunotherapyLactobacillus

Identifiers

PMID40791867
PMCPMC12336454

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.